Search Results - "Liljenquist, David R"

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes by Davis, Asa K, DuBose, Stephanie N, Haller, Michael J, Miller, Kellee M, DiMeglio, Linda A, Bethin, Kathleen E, Goland, Robin S, Greenberg, Ellen M, Liljenquist, David R, Ahmann, Andrew J, Marcovina, Santica M, Peters, Anne L, Beck, Roy W, Greenbaum, Carla J

“…It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment…”
Get full text

Testing a new platform to screen disease-modifying therapy in type 1 diabetes by Lord, Sandra M, Bahnson, Henry T, Greenbaum, Carla J, Liljenquist, David R, Virostko, John, Speake, Cate

“…Studies of new therapies to preserve insulin secretion in early type 1 diabetes require several years to recruit eligible subjects and to see a treatment…”
Get full text

35-LB: Reliability of an Artificial Intelligence (AI) Diabetic Retinopathy (DR) Detection System by IPP, ELI, LILJENQUIST, DAVID R.

“…A prospective study (NCT04302012) evaluated the reliability of the EyeArt AI DR detection system (Eyenuk, Inc.) across repeated examinations, operators, and…”
Get full text

Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes by Alva, Shridhara, Bailey, Timothy, Brazg, Ronald, Budiman, Erwin S., Castorino, Kristin, Christiansen, Mark P., Forlenza, Gregory, Kipnes, Mark, Liljenquist, David R., Liu, Hanqing

“…Background: In this study, we evaluated the analytical performance of the second-generation factory-calibrated FreeStyle Libre Flash Glucose Monitoring…”
Get full text

Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System by Alva, Shridhara, Brazg, Ronald, Castorino, Kristin, Kipnes, Mark, Liljenquist, David R., Liu, Hanqing

“…Introduction We have evaluated the performance of the FreeStyle Libre® 3 continuous glucose monitoring system (FSL3) compared to (1) the venous plasma…”
Get full text

Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes by Forlenza, Gregory P, Pinhas-Hamiel, Orit, Liljenquist, David R, Shulman, Dorothy I, Bailey, Timothy S, Bode, Bruce W, Wood, Michael A, Buckingham, Bruce A, Kaiserman, Kevin B, Shin, John, Huang, Suiying, Lee, Scott W, Kaufman, Francine R

“…To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D). Participants (N = 105,…”
Get more information

76-LB: Performance of FreeStyle Libre 3 System by KARINKA, SHRIDHARA A., BRAZG, RONALD L., CASTORINO, KRISTIN N., LILJENQUIST, DAVID R., KIPNES, MARK, LIU, HANQING

“…FreeStyle Libre 3 is the next generation FreeStyle Libre system with the same sensor tail but an on-body component that is about 70% smaller than Libre 2. We…”
Get full text

Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial by Forlenza, Gregory P., Ekhlaspour, Laya, DiMeglio, Linda A., Fox, Larry A., Rodriguez, Henry, Shulman, Dorothy I., Kaiserman, Kevin B., Liljenquist, David R., Shin, John, Lee, Scott W., Buckingham, Bruce A.

“…Background Highly variable insulin sensitivity, susceptibility to hypoglycemia and inability to effectively communicate hypoglycemic symptoms pose significant…”
Get full text

Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes by Weinstock, Ruth S, DuBose, Stephanie N, Bergenstal, Richard M, Chaytor, Naomi S, Peterson, Christina, Olson, Beth A, Munshi, Medha N, Perrin, Alysa J S, Miller, Kellee M, Beck, Roy W, Liljenquist, David R, Aleppo, Grazia, Buse, John B, Kruger, Davida, Bhargava, Anuj, Goland, Robin S, Edelen, Rachel C, Pratley, Richard E, Peters, Anne L, Rodriguez, Henry, Ahmann, Andrew J, Lock, John-Paul, Garg, Satish K, Rickels, Michael R, Hirsch, Irl B

“…Severe hypoglycemia is common in older adults with long-standing type 1 diabetes, but little is known about factors associated with its occurrence. A…”
Get full text

Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial by Carlson, Anders L., Graham, Timothy E., Akturk, Halis K., Liljenquist, David R., Bergenstal, Richard M., Sulik, Becky, Shah, Viral N., Sulik, Mark, Zhao, Peter, Briggs, Peter, Sassan-Katchalski, Ravid, Pinsker, Jordan E.

“…Background: Control-IQ technology version 1.5 allows for a wider range of weight and total daily insulin (TDI) entry, in addition to other changes to enhance…”
Get full text

Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial by Garg, Satish K, Grunberger, George, Weinstock, Ruth, Lawson, Margaret L, Hirsch, Irl B, DiMeglio, Linda A, Pop-Busui, Rodica, Philis-Tsimikas, Athena, Kipnes, Mark, Liljenquist, David R, Brazg, Ronald L, Kudva, Yogish C, Buckingham, Bruce A, McGill, Janet B, Carlson, Anders L, Criego, Amy B, Christiansen, Mark P, Kaiserman, Kevin B, Griffin, Kurt J, Forlenza, Greg P, Bode, Bruce W, Slover, Robert H, Keiter, Ashleigh, Ling, Chenxiao, Marinos, Briggitte, Cordero, Toni L, Shin, John, Lee, Scott W, Rhinehart, Andrew S, Vigersky, Robert A

“…To evaluate safety and effectiveness of MiniMed™ 670G hybrid closed loop (HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for 6…”
Get more information

Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome by Ehrmann, David A., Liljenquist, David R., Kasza, Kristen, Azziz, Ricardo, Legro, Richard S., Ghazzi, Mahmoud N.

“…Context: Polycystic ovary syndrome (PCOS) and the metabolic syndrome have many features in common and may share the same pathogenesis. Objective: This study…”
Get full text

672-P: Performance of a New Disposable Zero-Calibration Continuous Glucose Monitoring (CGM) Sensor by BODE, BRUCE W., BAILEY, TIMOTHY S., CASTORINO, KRISTIN N., CHRISTIANSEN, MARK P., GARG, SATISH K., KAISERMAN, KEVIN B., LILJENQUIST, DAVID R., SHULMAN, DOROTHY I., SLOVER, ROBERT H., SHIN, JOHN, PENG, FEN, HUANG, SUIYING, RHINEHART, ANDREW S., VIGERSKY, ROBERT A.

“…Objective: A CGM sensor that is disposable and requires no calibration may make glucose management easier for people living with diabetes. The present study…”
Get full text

149-OR: Evaluation of the Next Generation 180-Day Long-Term Implantable Eversense CGM System: PROMISE Study by GARG, SATISH K., LILJENQUIST, DAVID R., BODE, BRUCE W., CHRISTIANSEN, MARK P., BAILEY, TIMOTHY S., BRAZG, RONALD L., DENHAM, DOUGLAS S., CHANG, ANNA, AKTURK, HALIS K., DEHENNIS, ANDREW D., TWEDEN, KATHERINE, KAUFMAN, FRANCINE R.

“…Background: The prospective, multi-center PROMISE study evaluated the safety and accuracy of the next generation Eversense CGM System for up to 180 days in 181…”
Get full text

100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results by VIGERSKY, ROBERT A., BODE, BRUCE W., BRAZG, RONALD L., BUCKINGHAM, BRUCE A., CARLSON, ANDERS L., KAISERMAN, KEVIN B., KIPNES, MARK, LILJENQUIST, DAVID R., PHILIS-TSIMIKAS, ATHENA, PIHOKER, CATHERINE, POP-BUSUI, RODICA, REED, JOHN, SHERR, JENNIFER, SHULMAN, DOROTHY I., SLOVER, ROBERT H., THRASHER, JAMES, CHEN, XIAOXIAO, LIU, MARGARET, CORDERO, TONI L., VELLA, MELISSA, RHINEHART, ANDREW S., SHIN, JOHN

“…Background: Safety and effectiveness outcomes of individuals using the MiniMed™ 780G system with the no-calibration Guardian™ 4 sensor during the first three…”
Get full text

910-P: Improved Accuracy of 14-Day Factory-Calibrated FreeStyle Libre System with New Glucose Algorithm by KARINKA, SHRIDHARA ALVA, BAILEY, TIMOTHY S., BRAZG, RONALD L., BUDIMAN, ERWIN S., CASTORINO, KRISTIN, CHRISTIANSEN, MARK P., LILJENQUIST, DAVID R., LIU, HANQING

“…We evaluated the accuracy of FreeStyle Libre 14-day system with new glucose algorithm in adults ages 18 years or older. This was a non-randomized,…”
Get full text

231-LB: Innovative Blood Sampling Technology for Convenient, Nearly Painless, and Accurate Monitoring of Diabetes by ROMEO, ELISA, BRYANT-GREENWOOD, PETER K., CASTORINO, KRISTIN N., LILJENQUIST, DAVID R., JORDAN, BRETT L., HARRINGTON, MINDY, HOLSCHER, TODD, ALEXANDER, CLAIRE, DOKUKIN, VICTOR, NERLEKAR, MUKUL, WILLIAMSON, LUCY, SLOANE, JESSICA

“…Monitoring HbA1c levels in individuals affected by diabetes remains the standard of care for ensuring proper management of the condition. Typically, HbA1c is…”
Get full text

97-LB: Safety and Glycemic Outcomes of the MiniMed Advanced Hybrid Closed-Loop (AHCL) System in Subjects with T1D by CARLSON, ANDERS L., BODE, BRUCE W., BRAZG, RONALD L., CHRISTIANSEN, MARK P., GARG, SATISH K., KAISERMAN, KEVIN, KIPNES, MARK, LILJENQUIST, DAVID R., PHILIS-TSIMIKAS, ATHENA, POP-BUSUI, RODICA, SHERR, JENNIFER, SHULMAN, DOROTHY I., SINGH, KAMALPREET K., SLOVER, ROBERT H., THRASHER, JAMES, CHEN, XIAOXIAO, GROSMAN, BENYAMIN, LEE, SCOTT W., LINTEREUR, LOUIS J., LIU, MARGARET, PARIKH, NEHA, RHINEHART, ANDREW S., PENG, FEN, ROY, ANIRBAN, SHIN, JOHN, WU, DI, VIGERSKY, ROBERT

“…Background: Automated insulin delivery systems improve glycemic control including time spent in, below and above range (TIR, TBR and TAR, respectively) in…”
Get full text

In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes by Wood, Michael A, Shulman, Dorothy I, Forlenza, Gregory P, Bode, Bruce W, Pinhas-Hamiel, Orit, Buckingham, Bruce A, Kaiserman, Kevin B, Liljenquist, David R, Bailey, Timothy S, Shin, John, Huang, Suiying, Chen, Xiaoxiao, Cordero, Toni L, Lee, Scott W, Kaufman, Francine R

“…The Medtronic predictive low-glucose management (PLGM) algorithm automatically stops insulin delivery when sensor glucose (SG) is predicted to reach or fall…”
Get more information

1059-P: Glycemic Outcomes from the MiniMed™ 670G System Pivotal Trials in Patients 2-75 Years of Age by BAILEY, TIMOTHY S., BODE, BRUCE W., BUCKINGHAM, BRUCE A., FORLENZA, GREGORY P., PINHAS-HAMIEL, ORIT, KAISERMAN, KEVIN, LILJENQUIST, DAVID R., SHULMAN, DOROTHY I., WOOD, MICHAEL A., CHEN, XIAOXIAO, SHIN, JOHN, CORDERO, TONI L., LEE, SCOTT W., KAUFMAN, FRANCINE R.

“…Background: The MiniMed™ 670G system is FDA-approved and CE-marked for patients with T1D aged ≥7 years. Glycemic outcomes of patients aged 2-75 years with T1D…”
Get full text